FDA Grants NKore BioTherapeutics, Inc. a Type B Pre-IND Meeting for Lead Supercharged NK Cell Therapy Candidate NK101
The scheduled meeting marks the Company's first formal regulatory interaction with the FDA in support of a planned U.S. IND filing LOS ANGELES, CA, UNITED STATES, July 29, 2026 /EINPresswire.com/ -- Los Angeles, Calif. — July 29, 2026 — …